Natasha Mason

Natasha Mason is interested in elucidating the neurobiological and cognitive mechanisms of (psychedelic) drugs by utilizing multimodal study designs, with a particular focus on substances that may hold therapeutic value.

CV

Natasha L. Mason MSc, is a Ph.D. student at the University Of Maastricht, Department of Neuropsychology & Psychopharmacology. She has a background in (neuro)psychology and pharmacy.

Notable Research Papers

• Me, myself, bye: regional alterations in glutamate and the experience of ego dissolution with psilocybin (Mason et al., 2020)
• Sub-Acute Effects of Psilocybin on Empathy, Creative Thinking, and Subjective Well-Being (Mason et al., 2019)
• A single inhalation of vapor from dried toad secretion containing 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in a naturalistic setting is related to sustained enhancement of satisfaction with life, mindfulness-related capacities, and a decrement of psychopathological symptoms (Uthaug et al., 2019)

Find more on Google Scholar or PubMed

Media

She has given public talks:

• Natasha Mason – (Sub-)Acute Effects of Psilocybin on Creativity, Empathy and Satisfaction with Life (Breaking Convention, 2019)
• Natasha Mason – Psychedelics & Cognitive Flexibility: Therapeutic Implications (Paradigm Lost a symposium organized by APRA, 2018)

More media:

• A single dose of psilocybin enhances creative thinking and empathy up to seven days after use, study finds (PsyPost, February 2020)
• People with low psychological well-being more likely to report positive outcomes after psychedelic use (Psypost, March 2020)
• Breakthrough psilocybin study uncovers neurochemical origins of human ego (NewAtlas, June 2020)